Libang Instruments announced stock trading changes in the morning, stating that the company disclosed on March 15 that the company and Global Health Labs, Inc signed an agreement on an artificial intelligence ultrasound project in Bellevue, Washington, USA. Currently, this artificial intelligence-driven economical handheld ultrasound device (“product” for short) uses AI technology to identify diagnostic parameters of pre-natal fetuses from blindly scanned ultrasound videos by installing AI-based antenatal screening functions on handheld ultrasound to assist in identifying early risks for mothers and fetuses. Currently, other manufacturers on the market already sell similar products based on similar technology. The product developed by the company is still in the joint development stage between the two parties, and the relevant regulatory approval and registration process has not yet been carried out. The specific amount of funding received by the company from Global Health Labs, Inc., needs to be determined in batches based on the progress of the R&D project. Currently, this product has not generated order revenue. Since future sales revenue is affected by objective factors such as R&D project progress and registration progress, it is impossible to predict the extent of the impact on the company's performance for the time being.